Amid global expansion, India's GVK focuses on clinical development

Indian CRO GVK Biosciences has spent the last year transitioning from a discovery-focused contractor to a full-service developer, now launching a dedicated clinical research unit to reach drugmakers around the world.

Dubbed Clinogent, GVK's clinical arm provides end-to-end services for pharma, biotech and generics outfits, the company said. Through buyouts, partnerships and brick-and-mortar expansions, GVK has reached into biologics development, late-stage trials and manufacturing, and Clinogent is meant to be the catch-all home of the CRO's clinical operation, CEO Manni Kantipudi said.

The global market for clinical development services sits at around $16 billion today, according to GVK, and the CRO expects it to grow at about 10% a year to reach $23 billion in 2020. The CRO's evolution into a full-service outsourcer will help GVK better capitalize on the boom, Kantipudi said in a statement.

"Clinogent will be a unique clinical development service provider from India, as it will be able to address the clinical needs of both innovator biopharmaceutical and generics companies worldwide," he said. "I am confident this step will bring greater focus on delivering innovative and intelligent solutions and will make significant contributions in the clinical development value chain of our customers."

The fast-expanding CRO has quickly transitioned from a local player into an international force, making its way into the U.S. through a buyout of California's Aragen Bioscience earlier this year. Among the CRO's clients are Astellas, Bayer, Endo Health Solutions ($ENDP), Onconova ($ONTX) and the FDA.

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.